Daniel T. Milton

3.0k total citations · 2 hit papers
27 papers, 2.4k citations indexed

About

Daniel T. Milton is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Daniel T. Milton has authored 27 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Daniel T. Milton's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Daniel T. Milton is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Daniel T. Milton collaborates with scholars based in United States, Australia and United Kingdom. Daniel T. Milton's co-authors include William Pao, John R. Strawn, Sarah Temin, Giuseppe Giaccone, David H. Johnson, Mark G. Kris, Christopher G. Azzoli, Vincent A. Miller, Julie R. Brahmer and Joan H. Schiller and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Daniel T. Milton

27 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

2009 752 citations Christopher G. Azzoli, Sherman Baker et al. Journal of Clinical Oncology profile →
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

2011 399 citations Sarah Temin, Mary Beth Beasley et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel T. Milton United States	16	1.9k	1.6k	587	383	128	27	2.4k
Purvish Parikh India	9	2.1k 1.1×	1.8k 1.1×	521 0.9×	412 1.1×	99 0.8×	21	2.6k
Miloš Pešek Czechia	21	1.7k 0.9×	1.6k 1.0×	650 1.1×	408 1.1×	74 0.6×	110	2.4k
Georgina Speake United Kingdom	11	1.8k 1.0×	1.5k 0.9×	583 1.0×	532 1.4×	135 1.1×	16	2.3k
H. Spiridonidis United States	4	1.8k 0.9×	1.7k 1.0×	541 0.9×	288 0.8×	113 0.9×	8	2.1k
Patrick Peterson United States	21	2.2k 1.2×	1.8k 1.1×	472 0.8×	310 0.8×	90 0.7×	55	2.6k
Kathryn H. Brown United Kingdom	15	1.8k 0.9×	1.4k 0.9×	931 1.6×	460 1.2×	134 1.0×	30	2.4k
Richard Eek Australia	9	2.0k 1.1×	2.1k 1.3×	652 1.1×	326 0.9×	165 1.3×	39	2.7k
Cesare Gridelli Italy	18	2.4k 1.3×	2.1k 1.3×	527 0.9×	270 0.7×	60 0.5×	37	2.9k
E.H. Tan Singapore	8	2.0k 1.1×	1.8k 1.1×	544 0.9×	367 1.0×	92 0.7×	23	2.4k
Annetta Krebs United States	8	1.9k 1.0×	2.0k 1.2×	723 1.2×	395 1.0×	124 1.0×	8	2.8k

Countries citing papers authored by Daniel T. Milton

Since Specialization

Citations

This map shows the geographic impact of Daniel T. Milton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel T. Milton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel T. Milton more than expected).

Fields of papers citing papers by Daniel T. Milton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel T. Milton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel T. Milton. The network helps show where Daniel T. Milton may publish in the future.

Co-authorship network of co-authors of Daniel T. Milton

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel T. Milton. A scholar is included among the top collaborators of Daniel T. Milton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel T. Milton. Daniel T. Milton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Azzoli, Christopher G., Sarah Temin, Timothy Aliff, et al.. (2011). 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(28). 3825–3831. 234 indexed citations

Beasley, Mary Beth & Daniel T. Milton. (2011). ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice. Journal of Oncology Practice. 7(3). 202–204. 25 indexed citations

Azzoli, Christopher G., Sherman Baker, Sarah Temin, et al.. (2009). American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(36). 6251–6266. 752 indexed citations breakdown →

Milton, Daniel T., et al.. (2009). Built-in Self-Test for Memory Resources in Virtex-4 Field Programmable Gate Arrays.. Computers and Their Applications. 63–68. 5 indexed citations

Radhakrishnan, Amruta, et al.. (2009). Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial. Journal of Chemotherapy. 21(4). 439–444. 6 indexed citations

Patel, Jyoti D., Thomas A. Hensing, Alfred Rademaker, et al.. (2009). Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(20). 3284–3289. 139 indexed citations

Patel, Jyoti D., Thomas A. Hensing, Eric Hart, et al.. (2008). Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 8044–8044. 11 indexed citations

Riely, Gregory J., Naiyer A. Rizvi, Mark G. Kris, et al.. (2008). Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(2). 264–270. 39 indexed citations

Krug, Lee M., Daniel T. Milton, Achim A. Jungbluth, et al.. (2007). Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels. Journal of Thoracic Oncology. 2(10). 947–952. 36 indexed citations

10.

Milton, Daniel T., Gregory J. Riely, Christopher G. Azzoli, et al.. (2007). Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer. Cancer. 110(3). 599–605. 81 indexed citations

11.

Riely, Gregory J., Mark G. Kris, Binsheng Zhao, et al.. (2007). Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus. Clinical Cancer Research. 13(17). 5150–5155. 237 indexed citations

12.

Nabhan, Chadi, Brian L. Samuels, Daniel T. Milton, et al.. (2007). Mitomycin-C/5-Fluorouracil/Leucovorin and Hyperfractionated Radiation Therapy for Rectal Carcinoma: A Phase II Study with Long-Term Follow-up. Clinical Colorectal Cancer. 6(6). 436–441. 2 indexed citations

13.

Milton, Daniel T., et al.. (2006). Embedded Processor Based Built-In Self-Test and Diagnosis of Logic and Memory Resources in FPGAs.. European Symposium on Algorithms. 87–93. 9 indexed citations

14.

Milton, Daniel T., Christopher G. Azzoli, Robert T. Heelan, et al.. (2006). A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer. 107(5). 1034–1041. 65 indexed citations

15.

Milton, Daniel T., Gregory J. Riely, William Pao, et al.. (2006). Molecular On/Off Switch. Journal of Clinical Oncology. 24(30). 4940–4942. 10 indexed citations

16.

Omuro, Antonio, Mark G. Kris, Vincent A. Miller, et al.. (2005). High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 103(11). 2344–2348. 184 indexed citations

17.

Milton, Daniel T. & Vincent A. Miller. (2005). Advances in Cytotoxic Chemotherapy for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer. Seminars in Oncology. 32(3). 299–314. 15 indexed citations

18.

Milton, Daniel T., Mark G. Kris, Jorge Gómez, & Marc B. Feinstein. (2004). Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). Supportive Care in Cancer. 13(1). 70–72. 13 indexed citations

19.

Kirsch, Andrew J., Daniel T. Milton, Gregory Dean, et al.. (1993). Preliminary results of laser tissue welding in extravesical reimplantation of the ureters. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 1876. 168–168. 3 indexed citations

20.

Parker, N., et al.. (1992). A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/ WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer. Cancer. 70(5). 1062–1068. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact